162 related articles for article (PubMed ID: 34725049)
1. Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto
Kiltz U; Braun J
Ann Rheum Dis; 2023 Dec; 82(12):e229. PubMed ID: 34725049
[No Abstract] [Full Text] [Related]
2. Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng.
Molto A; van der Heijde D; Van den Bosch FE; Dougados M
Ann Rheum Dis; 2023 Jul; 82(7):e167. PubMed ID: 34187778
[No Abstract] [Full Text] [Related]
3. Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'.
Wang W; Lee YH; Wei JCC
Ann Rheum Dis; 2023 Nov; 82(11):e223. PubMed ID: 34226191
[No Abstract] [Full Text] [Related]
4. Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'.
Cai G; Peng X
Ann Rheum Dis; 2023 Jul; 82(7):e166. PubMed ID: 34187774
[No Abstract] [Full Text] [Related]
5. Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun
Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RB; van der Heijde D
Ann Rheum Dis; 2023 Sep; 82(9):e206. PubMed ID: 36878690
[No Abstract] [Full Text] [Related]
6. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
Siebert S; Marzo-Ortega H
Ann Rheum Dis; 2023 Aug; 82(8):e185. PubMed ID: 34844925
[No Abstract] [Full Text] [Related]
7. Tight control and treat-to-target in axial spondyloarthritis. Where are we?
Wendling D; Claudepierre P; Goupille P; Pham T; Prati C
Joint Bone Spine; 2022 Jan; 89(1):105263. PubMed ID: 34506936
[No Abstract] [Full Text] [Related]
8. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Lavie F; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar AA; Østergaard M; Baraliakos X
Ann Rheum Dis; 2023 Aug; 82(8):e187. PubMed ID: 35487679
[No Abstract] [Full Text] [Related]
9. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physicianreported spondylitis'?' by Siebert and Marzo-Ortega.
Braun J; Landewé RB
Ann Rheum Dis; 2023 Aug; 82(8):e186. PubMed ID: 34844931
[No Abstract] [Full Text] [Related]
10. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Gladman.
Landewé RB; Braun J
Ann Rheum Dis; 2023 Aug; 82(8):e188. PubMed ID: 35487678
[No Abstract] [Full Text] [Related]
11. Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update".
Braun J
Ann Rheum Dis; 2023 Sep; 82(9):e205. PubMed ID: 36737105
[No Abstract] [Full Text] [Related]
12. Is the Difficult-to-Treat (D2T) concept applicable to axial spondyloarthritis?
Wendling D; Verhoeven F; Prati C
Joint Bone Spine; 2023 May; 90(3):105512. PubMed ID: 36528335
[No Abstract] [Full Text] [Related]
13. Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
Huang JX; Leong PY; Wei JC
Ann Rheum Dis; 2022 Nov; 81(11):e226. PubMed ID: 32933918
[No Abstract] [Full Text] [Related]
14. Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
Ciurea A; Micheroli R
Ann Rheum Dis; 2022 Nov; 81(11):e227. PubMed ID: 32933922
[No Abstract] [Full Text] [Related]
15. Correspondence on: 'Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Wallman
Proft F; Protopopov M; Rios Rodriguez V; Torgutalp M; Siegmund B; Poddubnyy D
Ann Rheum Dis; 2022 Jan; 81(1):e9. PubMed ID: 31818807
[No Abstract] [Full Text] [Related]
16. Response to: 'Correspondence on: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft
Wallman JK; Mogard E; Marsal J; Andréasson K; Jöud A; Geijer M; Kristensen LE; Lindqvist E; Olofsson T
Ann Rheum Dis; 2022 Jan; 81(1):e10. PubMed ID: 31892532
[No Abstract] [Full Text] [Related]
17. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.
Molto A; López-Medina C; Van den Bosch FE; Boonen A; Webers C; Dernis E; van Gaalen FA; Soubrier M; Claudepierre P; Baillet A; Starmans-Kool M; Spoorenberg A; Jacques P; Carron P; Joos R; Lenaerts J; Gossec L; Pouplin S; Ruyssen-Witrand A; Sparsa L; van Tubergen A; van der Heijde D; Dougados M
Ann Rheum Dis; 2021 Nov; 80(11):1436-1444. PubMed ID: 33958325
[TBL] [Abstract][Full Text] [Related]
18. Disease Activity Assessment in Nonradiographic Axial Spondyloarthritis: Is It Time to Move Beyond the Bath Ankylosing Spondylitis Disease Activity Index or Ankylosing Spondylitis Disease Activity Score? Comment on the Article by Rusman et al.
Mishra D; Harish BV; Gadde S; Patro PS
Arthritis Rheumatol; 2021 Dec; 73(12):2351-2352. PubMed ID: 34180157
[No Abstract] [Full Text] [Related]
19. Current aspects for the treatment of axial spondyloarthritis.
Ku CH; Lee YH; Wei JC; Braun J
Int J Rheum Dis; 2023 Jan; 26(1):5-7. PubMed ID: 36591903
[No Abstract] [Full Text] [Related]
20. [Axial spondyloarthritis : Update on management based on the interdisciplinary S3 guidelines on axial spondyloarthritis including early forms and ankylosing spondylitis].
Kiefer D; Braun J; Kiltz U
Z Rheumatol; 2022 Apr; 81(3):198-204. PubMed ID: 35113204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
